In conclusion, this study confirms the increased efficacy of SCT after anti-PD-(L)1 agents in patients with pre-treated R/M HNSCC, while it identifies potential predictors of benefit that may aid treatment decision-making in clinical practice. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.